Takepron is a proton pump inhibitor discovered by Takeda Pharmaceutical and has been launched since 1992 in Japan.
Takeda Pharmaceutical said that administration of low-dose aspirin for a long period sometimes causes gastric or duodenal ulcer, however, discontinuing of administration may make patients face a higher risk of forming blood clots and emboli. Therefore, it is considered that extended use of low-dose aspirin while preventing an onset of ulcers is important.
Takeda Pharmaceutical claimed that there have been no drugs which have an indication for prevention of ulcers during low-dose aspirin administration in Japan, it submitted an application for an additional indication of Takepron capsules 15 and Takepron OD tablets 15.
Yasuhiko Yamanaka, a member of the board, senior vice president of pharmaceutical marketing division at Takeda Pharmaceutical, said: “With the approval of this additional indication, we expect that Takepron helps patients who have a history of ulcers and take low-dose aspirin to prevent recurrence of ulcers.”